Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions

JAMA. 2016 Mar 15;315(11):1107-8. doi: 10.1001/jama.2016.2240.

Authors

Melissa A Robb¹, Pamela M McInnes², Robert M Califf³

Affiliations

¹ Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.
³ US Food and Drug Administration, Silver Spring, Maryland.

PMID: 26978201
DOI: 10.1001/jama.2016.2240

No abstract available

MeSH terms

Biomarkers*
Consensus*
Equipment and Supplies
Genetic Markers
National Institutes of Health (U.S.)
Pharmaceutical Preparations
Terminology as Topic*
United States
United States Food and Drug Administration

Substances

Biomarkers
Genetic Markers
Pharmaceutical Preparations